Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F

New England Journal of Medicine

Volumn 374, Issue 1, 2016, Pages 54-61

  Shaw, Alice T ^a   Friboulet, Luc ^a   Leshchiner, Ignaty ^c   Gainor, Justin F ^a   Bergqvist, Simon ^d   Brooun, Alexei ^d   Burke, Benjamin J ^d   Deng, Ya Li ^d   Liu, Wei ^d   Dardaei, Leila ^a   Frias, Rosa L ^a   Schultz, Kate R ^a   Logan, Jennifer ^a   James, Leonard P ^d   Smeal, Tod ^d   Timofeevski, Sergei ^d   Katayama, Ryohei ^e   Iafrate, A John ^b   Le, Long ^b   McTigue, Michele ^d   Getz, Gad ^a,b,c   Johnson, Ted W ^d   Engelman, Jeffrey A ^a   more..

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d PFIZER INC   (United States)

^e CANCER CHEMOTHERAPY CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

7-AMINO-12-FLUORO-2,10,16-TRIMETHYL-15-OXO-10,15,16,17-TETRAHYDRO-2H-8,4-(METHENO)PYRAZOLO(4,3-H)(2,5,11)BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE; ANAPLASTIC LYMPHOMA KINASE; CERITINIB; CRIZOTINIB; MACROCYCLIC LACTAM; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; SULFONE;

ANTAGONISTS AND INHIBITORS; BINDING SITE; CARCINOMA, NON-SMALL-CELL LUNG; CASE REPORT; CHEMICAL STRUCTURE; CLINICAL TRIAL; DRUG RESISTANCE; FEMALE; GENETICS; HUMAN; LIVER FAILURE; LIVER TUMOR; LUNG NEOPLASMS; MIDDLE AGED; MUTATION; PHASE 1 CLINICAL TRIAL; SECONDARY;

BINDING SITES; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LACTAMS, MACROCYCLIC; LIVER FAILURE; LIVER NEOPLASMS; LUNG NEOPLASMS; MIDDLE AGED; MOLECULAR STRUCTURE; MUTATION; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; PYRIMIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; SULFONES;

EID: 84954050562     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1508887     Document Type: Article

References (23)

1. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
2. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
3. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
4. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6.
5. Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012;367:2075-88.
6. Jänne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 2015;372:1689-99.
7. Sequist LV, Soria JC, Goldman JW, et al. Rociletinib in EGFR-mutated non-smallcell lung cancer. N Engl J Med 2015;372:1700-9.
8. Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non-smallcell lung cancer. N Engl J Med 2014;370:1189-97.
9. Gadgeel SM, Gandhi L, Riely GJ, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALKrearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol 2014;15:1119-28.
10. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703.
11. Katayama R, Lovly CM, Shaw AT. Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine. Clin Cancer Res 2015;21:2227-35.
12. Camidge DR, Bazhenova L, Salgia R, et al. Safety and efficacy of brigatinib (AP26113) in advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC). J Clin Oncol 2015;33:8062. abstract.
13. Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov 2014;4:662-73.
14. Katayama R, Yanagitani N, Koike S, et al. Resistance mechanisms to ALK inhibitors. Philadelphia: American Association for Cancer Research, 2015.
15. Johnson TW, Richardson PF, Bailey S, et al. Discovery of (10R)-7-amino-12-fluoro-2, 10, 16-trimethyl-15-oxo-10, 15, 16, 17-tetrahydro-2H-8, 4-(metheno) pyrazolo [4, 3-h][2, 5, 11]-benzoxadiazacyclotetra decine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALKresistant mutations. J Med Chem 2014;57:4720-44.
16. Zou HY, Friboulet L, Kodack DP, et al. PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models. Cancer Cell 2015;28:70-81.
17. Choi YL, Soda M, Yamashita Y, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010;363:1734-9.
18. Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 2014;371:1963-71.
19. Zheng Z, Liebers M, Zhelyazkova B, et al. Anchored multiplex PCR for targeted next-generation sequencing. Nat Med 2014;20:1479-84.
20. Gouji T, Takashi S, Mitsuhiro T, Yukito I. Crizotinib can overcome acquired resistance to CH5424802: is amplification of the MET gene a key factor? J Thorac Oncol 2014;9(3):e27-8.
21. Murugan AK, Xing M. Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene. Cancer Res 2011;71:4403-11.
22. Ceccon M, Mologni L, Giudici G, et al. Treatment efficacy and resistance mechanisms using the second-generation ALK Inhibitor AP26113 in human NPM-ALKpositive anaplastic large cell lymphoma. Mol Cancer Res 2015;13:775-83.
23. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinumcontaining chemotherapy regimens. J Clin Oncol 2000;18:2354-62.